BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, Barnes E, Brainard DM, Massetto B, Lin M, Han B, McHutchison JG, Subramanian GM, Cooper C, Agarwal K; BOSON Study Group. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015;149:1462-70. [PMID: 26248087 DOI: 10.1053/j.gastro.2015.07.043] [Cited by in Crossref: 170] [Cited by in F6Publishing: 151] [Article Influence: 24.3] [Reference Citation Analysis]
Number Citing Articles
1 Huang Y, Li MH, Hou M, Xie Y. Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. Hepatobiliary Pancreat Dis Int 2017;16:470-9. [PMID: 28992878 DOI: 10.1016/S1499-3872(17)60044-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
2 Yu ML. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. J Gastroenterol Hepatol 2017;32:1436-42. [PMID: 28124463 DOI: 10.1111/jgh.13747] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
3 Berden FA, Aaldering BR, Groenewoud H, IntHout J, Kievit W, Drenth JP. Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol 2017;15:349-59. [PMID: 27840182 DOI: 10.1016/j.cgh.2016.10.034] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
4 Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Medical Journal of Australia 2016;204:268-72. [DOI: 10.5694/mja16.00106] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 7.7] [Reference Citation Analysis]
5 Yates MK, Seley-Radtke KL. The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold. Antiviral Res 2019;162:5-21. [PMID: 30529089 DOI: 10.1016/j.antiviral.2018.11.016] [Cited by in Crossref: 75] [Cited by in F6Publishing: 55] [Article Influence: 18.8] [Reference Citation Analysis]
6 Schneider MD, Sarrazin C. Management of HCV-Associated Liver Cirrhosis. Visc Med 2016;32:96-104. [PMID: 27413726 DOI: 10.1159/000445330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
7 Esteban R, Buti M. Therapy with direct-acting antivirals for genotype 3 patients: interferon's last gasp? Gastroenterology 2015;149:1326-30. [PMID: 26416329 DOI: 10.1053/j.gastro.2015.09.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, Pol S, Stuart K, Tse E, McPhee F, Bhore R, Jimenez-Exposito MJ, Thompson AJ. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology 2016;63:1430-41. [PMID: 26822022 DOI: 10.1002/hep.28473] [Cited by in Crossref: 184] [Cited by in F6Publishing: 178] [Article Influence: 30.7] [Reference Citation Analysis]
9 Andreoni M, Babudieri S, Bruno S, Colombo M, Zignego AL, Di Marco V, Di Perri G, Perno CF, Puoti M, Taliani G, Villa E, Craxì A. Current and future challenges in HCV: insights from an Italian experts panel. Infection 2018;46:147-63. [PMID: 29098647 DOI: 10.1007/s15010-017-1093-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
10 Satsangi S, Mehta M, Duseja A, Taneja S, Dhiman RK, Chawla Y. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C. J Gastroenterol Hepatol. 2017;32:859-863. [PMID: 27624314 DOI: 10.1111/jgh.13595] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
11 Tang L, Ward H, Kattakuzhy S, Wilson E, Kottilil S. Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. Expert Rev Gastroenterol Hepatol 2016;10:21-36. [PMID: 26558305 DOI: 10.1586/17474124.2016.1119042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
12 Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A, Forton DM, Fox R, Gordon F, Rosenberg WM, Mutimer DJ, Du J, Gilbert CL, Asante-Appiah E, Wahl J, Robertson MN, Barr E, Haber B. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. Hepatology. 2018;67:2113-2126. [PMID: 29473975 DOI: 10.1002/hep.29852] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
13 Yang YM, Choi EJ. Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials. Ther Clin Risk Manag 2017;13:477-97. [PMID: 28442915 DOI: 10.2147/TCRM.S134818] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 van Wilgenburg B, Scherwitzl I, Hutchinson EC, Leng T, Kurioka A, Kulicke C, de Lara C, Cole S, Vasanawathana S, Limpitikul W, Malasit P, Young D, Denney L;  STOP-HCV consortium; Moore MD, Fabris P, Giordani MT, Oo YH, Laidlaw SM, Dustin LB, Ho LP, Thompson FM, Ramamurthy N, Mongkolsapaya J, Willberg CB, Screaton GR, Klenerman P. MAIT cells are activated during human viral infections. Nat Commun. 2016;7:11653. [PMID: 27337592 DOI: 10.1038/ncomms11653] [Cited by in Crossref: 253] [Cited by in F6Publishing: 238] [Article Influence: 42.2] [Reference Citation Analysis]
15 Zarębska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, Janczewska E, Dybowska D, Pawłowska M, Halota W, Mazur W, Lorenc B, Janocha-Litwin J, Simon K, Piekarska A, Berak H, Klapaczyński J, Stępień P, Sobala-Szczygieł B, Citko J, Socha Ł, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Dobracka B, Krygier R, Białkowska-Warzecha J, Laurans Ł, Flisiak R. Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. J Clin Med 2021;10:3280. [PMID: 34362064 DOI: 10.3390/jcm10153280] [Reference Citation Analysis]
16 Croce D, Bonfanti M, Restelli U. Financial and feasibility implications of the treatment of hepatitis C virus in Italy: scenarios and perspectives. Clinicoecon Outcomes Res 2016;8:377-85. [PMID: 27540306 DOI: 10.2147/CEOR.S106769] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
17 Wei B, Ji F, Yeo YH, Ogawa E, Stave CD, Dang S, Li Z, Furusyo N, Cheung RC, Nguyen MH. Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia. BMJ Open Gastroenterol 2018;5:e000209. [PMID: 30147941 DOI: 10.1136/bmjgast-2018-000209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
18 Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016;43:1276-1292. [PMID: 27087015 DOI: 10.1111/apt.13633] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 15.8] [Reference Citation Analysis]
19 Feld JJ, Maan R, Zeuzem S, Kuo A, Nelson DR, Di Bisceglie AM, Manns MP, Sherman K, Frazier LM, Sterling R, Mailliard M, Schmidt M, Akushevich L, Vainorius M, Fried MW. Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. Clin Infect Dis 2016;63:776-83. [PMID: 27325691 DOI: 10.1093/cid/ciw387] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
20 Pafundi PC, Parrella A, Iossa D, Molaro R, Battimelli C, Falco E, Sodano G, Utili R, Durante-Mangoni E. Viability of pegIFNα-RBV for CHC in the direct acting antiviral era: a practical algorithm between efficacy and cost containment. J Chemother 2017;29:94-101. [PMID: 27351356 DOI: 10.1080/1120009X.2016.1171467] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Alghamdi AS, Alghamdi M, Sanai FM, Alghamdi H, Aba-Alkhail F, Alswat K, Babatin M, Alqutub A, Altraif I, Alfaleh F. SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol 2016;22 Suppl:S25-57. [PMID: 27538727 DOI: 10.4103/1319-3767.188067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
22 Lagging M, Wejstål R, Norkrans G, Karlström O, Aleman S, Weiland O, Castedal M, Westin J; Swedish Consensus Group. Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. Infect Dis (Lond) 2017;49:561-75. [PMID: 28293974 DOI: 10.1080/23744235.2017.1300682] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
23 Wehmeyer MH, Ingiliz P, Christensen S, Hueppe D, Lutz T, Simon KG, Schewe K, Boesecke C, Baumgarten A, Busch H, Rockstroh J, Schmutz G, Kimhofer T, Berger F, Mauss S, Schulze Zur Wiesch J. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03). J Med Virol 2018;90:304-12. [PMID: 28710853 DOI: 10.1002/jmv.24903] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
24 Lin SK, De Maio N, Pedergnana V, Wu CH, Thézé J, Wilson DJ, Barnes E, Ansari MA. Using host genetics to infer the global spread and evolutionary history of HCV subtype 3a. Virus Evol 2021;7:veab065. [PMID: 34532064 DOI: 10.1093/ve/veab065] [Reference Citation Analysis]
25 Kao JH, Ahn SH, Chien RN, Cho M, Chuang WL, Jeong SH, Liu CH, Paik SW. Urgency to treat patients with chronic hepatitis C in Asia. J Gastroenterol Hepatol 2017;32:966-74. [PMID: 28005275 DOI: 10.1111/jgh.13709] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
26 Gupta S, Rout G, Patel AH, Mahanta M, Kalra N, Sahu P, Sethia R, Agarwal A, Ranjan G, Kedia S, Acharya SK, Nayak B, Shalimar. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection. J Viral Hepat 2018;25:771-8. [DOI: 10.1111/jvh.12870] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
27 Quer J, Rodríguez-Frias F, Gregori J, Tabernero D, Soria ME, García-Cehic D, Homs M, Bosch A, Pintó RM, Esteban JI, Domingo E, Perales C. Deep sequencing in the management of hepatitis virus infections. Virus Res 2017;239:115-25. [PMID: 28040474 DOI: 10.1016/j.virusres.2016.12.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
28 Wing PAC, Jones M, Cheung M, DaSilva S, Bamford C, Jason Lee WY, Aranday-Cortes E, Da Silva Filipe A, McLauchlan J, Smith D, Irving W, Cunningham M, Ansari A, Barnes E, Foster GR. Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir. Gastroenterology 2019;157:692-704.e9. [PMID: 31078622 DOI: 10.1053/j.gastro.2019.05.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
29 Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Pontarolo R. Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. J Clin Pharm Ther 2016;41:478-85. [PMID: 27440554 DOI: 10.1111/jcpt.12426] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
30 Puri P, Saraswat VA, Dhiman RK, Anand AC, Acharya SK, Singh SP, Chawla YK, Amarapurkar DN, Kumar A, Arora A, Dixit VK, Koshy A, Sood A, Duseja A, Kapoor D, Madan K, Srivastava A, Kumar A, Wadhawan M, Goel A, Verma A, Shalimar, Pandey G, Malik R, Agrawal S. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. J Clin Exp Hepatol 2016;6:119-45. [PMID: 27493460 DOI: 10.1016/j.jceh.2016.07.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
31 Domínguez A, Bruguera M, Vidal J, Plans P, Salleras L. Community-based seroepidemiological survey of HCV infection in Catalonia, Spain. J Med Virol. 2001;65:688-693. [PMID: 11745932 DOI: 10.3109/23744235.2015.1113438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
32 Solomon SS, Sulkowski MS, Amrose P, Srikrishnan AK, McFall AM, Ramasamy B, Kumar MS, Anand S, Thomas DL, Mehta SH. Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT). J Viral Hepat 2018;25:37-46. [PMID: 28719029 DOI: 10.1111/jvh.12761] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
33 Soni S, Singh D, Aggarwal R, Veerapu NS. Enhanced fitness of hepatitis C virus increases resistance to direct-acting antivirals. J Gen Virol 2022;103. [PMID: 35133954 DOI: 10.1099/jgv.0.001699] [Reference Citation Analysis]
34 Smith DA, Fernandez-Antunez C, Magri A, Bowden R, Chaturvedi N, Fellay J, McLauchlan J, Foster GR, Irving WL, Simmonds P, Pedergnana V, Ramirez S, Bukh J, Barnes E, Ansari MA; STOP-HCV Consortium. Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. Nat Commun 2021;12:6105. [PMID: 34671027 DOI: 10.1038/s41467-021-25649-6] [Reference Citation Analysis]
35 Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme AM, Rockstroh JK. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Rev Med Virol 2016;26:408-34. [PMID: 27401933 DOI: 10.1002/rmv.1895] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
36 Zarębska-Michaluk D, Flisiak R, Jaroszewicz J, Janczewska E, Czauż-Andrzejuk A, Berak H, Horban A, Staniaszek A, Gietka A, Tudrujek M, Tomasiewicz K, Dybowska D, Halota W, Piekarska A, Sitko M, Garlicki A, Orłowska I, Simon K, Belica-Wdowik T, Baka-Ćwierz B, Mazur W, Białkowska J, Socha Ł, Wawrzynowicz-Syczewska M, Laurans Ł, Deroń Z, Lorenc B, Dobracka B, Tronina O, Pawłowska M. Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals? J Interferon Cytokine Res 2018;38:93-100. [PMID: 29443655 DOI: 10.1089/jir.2017.0113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
37 Chan A, Patel K, Naggie S. Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs 2017;77:131-44. [PMID: 28074358 DOI: 10.1007/s40265-016-0685-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
38 Pedergnana V, Irving WL, Barnes E, McLauchlan J, Spencer CCA. Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients. J Interferon Cytokine Res 2019;39:642-9. [PMID: 31260374 DOI: 10.1089/jir.2019.0013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Puri P, Anand AC, Saraswat VA, Acharya SK, Dhiman RK, Sarin SK, Singh SP, Chawla YK, Aggarwal R, Amarapurkar D, Arora A, Dixit VK, Sood A, Shah S, Duseja A, Kapoor D, Shalimar, Madan K, Pande G, Nagral A, Kar P, Koshy A, Puri AS, Eapen CE, Thareja S. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015. J Clin Exp Hepatol 2015;5:221-38. [PMID: 26628840 DOI: 10.1016/j.jceh.2015.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
40 Sidhu SS, Malhi NS, Goyal O, Singh R, Dutta U, Grover R, Sidhu JS, Nanda V, Saluja H, Bansal A, Singh G, Sehgal A, Kishore H, Sidhu S. Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study. Hepatol Int 2017;11:277-85. [PMID: 28361300 DOI: 10.1007/s12072-017-9794-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
41 Sáez-Royuela F, Badia E. Sofosbuvir plus ribavirin in Asian patients with chronic genotype 2 hepatitis C virus infection: history of a success? Liver Int 2016;36:1093-5. [PMID: 27059163 DOI: 10.1111/liv.13138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Smirne C, D'Avolio A, Bellan M, Gualerzi A, Crobu MG, Pirisi M. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose. Pharmacol Res Perspect 2021;9:e00811. [PMID: 34152088 DOI: 10.1002/prp2.811] [Reference Citation Analysis]
43 Loustaud-Ratti V, Debette-Gratien M, Jacques J, Alain S, Marquet P, Sautereau D, Rousseau A, Carrier P. Ribavirin: Past, present and future. World J Hepatol 2016; 8(2): 123-130 [PMID: 26807208 DOI: 10.4254/wjh.v8.i2.123] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
44 Ganesan A, Barakat K. Applications of computer-aided approaches in the development of hepatitis C antiviral agents. Expert Opin Drug Discov 2017;12:407-25. [PMID: 28164720 DOI: 10.1080/17460441.2017.1291628] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
45 Sundaram V, Kowdley KV. Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2016;10:13-20. [PMID: 26560449 DOI: 10.1586/17474124.2016.1116937] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
46 Craxì A, Perno CF, Viganò M, Ceccherini-silberstein F, Petta S, Aghemo A, Alberti A, Andreone P, Andreoni M, Bonora S, Brunetto MR, Bruno S, Caporaso N, Chirianni A, Ciancio A, Degasperi E, Di Perri G, Fagiuoli S, Ferrari C, Gaeta GB, Pellicelli A, Puoti M, Raimondo G, Taliani G, Villa E, Zignego AL. From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease 2016;48:995-1005. [DOI: 10.1016/j.dld.2016.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
47 Kattakuzhy S, Levy R, Rosenthal E, Tang L, Wilson E, Kottilil S. Hepatitis C genotype 3 disease. Hepatol Int 2016;10:861-70. [DOI: 10.1007/s12072-016-9748-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
48 Daniel KE, Saeian K, Rizvi S. Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment. J Viral Hepat 2020;27:195-204. [PMID: 31602715 DOI: 10.1111/jvh.13218] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
49 Domingo E, de Ávila AI, Gallego I, Sheldon J, Perales C. Viral fitness: history and relevance for viral pathogenesis and antiviral interventions. Pathog Dis 2019;77:ftz021. [PMID: 30980658 DOI: 10.1093/femspd/ftz021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
50 Tacke F, Günther R, Buggisch P, Klinker H, Schober A, John C, Lutz T, Pfeiffer-Vornkahl H, Niederau C, Cornberg M, Sarrazin C, Mauss S. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver Int 2017;37:205-11. [PMID: 27428297 DOI: 10.1111/liv.13206] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
51 Gimeno-Ballester V, Mar J, O'Leary A, Adams R, San Miguel R. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. Expert Rev Gastroenterol Hepatol 2017;11:85-93. [PMID: 27500437 DOI: 10.1080/17474124.2016.1222271] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
52 Abbas Z, Saad M, Nadeem R, Jawed F, Abbas M. Sofosbuvir and Ribavirin With or Without Pegylated Interferon for Hepatitis C Genotype 3: A Real World Experience. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.45525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
53 Abo-zeid Y, Mantovani G, Irving WL, Garnett MC. Synthesis of nucleoside-boronic esters hydrophobic pro-drugs: A possible route to improve hydrophilic nucleoside drug loading into polymer nanoparticles. Journal of Drug Delivery Science and Technology 2018;46:354-64. [DOI: 10.1016/j.jddst.2018.05.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
54 Ohmer S, Honegger J. New prospects for the treatment and prevention of hepatitis C in children. Curr Opin Pediatr. 2016;28:93-100. [PMID: 26709684 DOI: 10.1097/mop.0000000000000313] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
55 Chan J, Chung RT. Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions. Clinical Pharmacology in Drug Development 2017;6:147-63. [DOI: 10.1002/cpdd.338] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
56 Ku KS, Chodavarapu RK, Martin R, Miller MD, Mo H, Svarovskaia ES. Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6. J Clin Microbiol 2016;54:1835-41. [PMID: 27147726 DOI: 10.1128/JCM.00238-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Weiler N, Zeuzem S, Welker MW. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection. World J Gastroenterol 2016; 22(41): 9044-9056 [PMID: 27895394 DOI: 10.3748/wjg.v22.i41.9044] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
58 Valencia J, Alvaro-Meca A, Troya J, Cuevas G, Gutiérrez J, Morro A, Alvarez J, Pulido L, Cañamares I, Escobar I, Moreno S, Ryan P. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. Int J Drug Policy 2019;72:181-8. [PMID: 31253391 DOI: 10.1016/j.drugpo.2019.06.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
59 Liu TW, Tsai PC, Huang CI, Tsai YS, Wang SC, Ko YM, Lin CC, Chen KY, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. J Formos Med Assoc 2018;117:54-62. [PMID: 28389143 DOI: 10.1016/j.jfma.2017.02.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
60 Simmonds P, Cuypers L, Irving WL, McLauchlan J, Cooke GS, Barnes E, Ansari MA; STOP-HCV Consortium. Impact of virus subtype and host IFNL4 genotype on large-scale RNA structure formation in the genome of hepatitis C virus. RNA 2020;26:1541-56. [PMID: 32747607 DOI: 10.1261/rna.075465.120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
61 Gimeno-Ballester V, Buti M, San Miguel R, Riveiro M, Esteban R. Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review. J Viral Hepat 2017;24:904-16. [PMID: 27925386 DOI: 10.1111/jvh.12660] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
62 Murakawa M, Asahina Y, Nagata H, Nakagawa M, Kakinuma S, Nitta S, Kawai-kitahata F, Otani S, Kaneko S, Miyoshi M, Tsunoda T, Asano Y, Sato A, Itsui Y, Azuma S, Nouchi T, Furumoto Y, Asano T, Chuganji Y, Tohda S, Watanabe M. ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin: ITPA variants and SOF/RBV therapy in hepatitis C. Hepatol Res 2017;47:1212-8. [DOI: 10.1111/hepr.12867] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
63 Flisiak R, Zarębska-Michaluk D, Janczewska E, Staniaszek A, Gietka A, Mazur W, Tudrujek M, Tomasiewicz K, Belica-Wdowik T, Baka-Ćwierz B, Dybowska D, Halota W, Lorenc B, Sitko M, Garlicki A, Berak H, Horban A, Orłowska I, Simon K, Socha Ł, Wawrzynowicz-Syczewska M, Jaroszewicz J, Deroń Z, Czauż-Andrzejuk A, Citko J, Krygier R, Piekarska A, Laurans Ł, Dobracki W, Białkowska J, Tronina O, Pawłowska M. Treatment of HCV infection in Poland at the beginning of the interferon-free era-the EpiTer-2 study. J Viral Hepat 2018;25:661-9. [PMID: 29316039 DOI: 10.1111/jvh.12861] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
64 Johnson SW, Thompson DK, Raccor B. Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions. Curr Infect Dis Rep 2017;19:22. [PMID: 28421422 DOI: 10.1007/s11908-017-0578-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
65 Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016;16:e40959. [PMID: 27799966 DOI: 10.5812/hepatmon.guideline] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
66 Kamal SM. Hepatitis C Treatment in the Era of Direct-Acting Antiviral Agents. Hepatitis C in Developing Countries. Elsevier; 2018. pp. 209-46. [DOI: 10.1016/b978-0-12-803233-6.00017-5] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 Hézode C, Bronowicki JP. Ideal oral combinations to eradicate HCV: The role of ribavirin. J Hepatol. 2016;64:215-225. [PMID: 26409316 DOI: 10.1016/j.jhep.2015.09.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
68 Khan A, Al Balwi M, AlAyyar L, AlAbdulkareem I, Albekairy A, Aljumah A. Tracing the epidemic history of hepatitis C virus genotypes in Saudi Arabia. Infect Genet Evol 2017;52:82-8. [PMID: 28458032 DOI: 10.1016/j.meegid.2017.04.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
69 Wymant C, Hall M, Ratmann O, Bonsall D, Golubchik T, de Cesare M, Gall A, Cornelissen M, Fraser C; STOP-HCV Consortium, The Maela Pneumococcal Collaboration, and The BEEHIVE Collaboration. PHYLOSCANNER: Inferring Transmission from Within- and Between-Host Pathogen Genetic Diversity. Mol Biol Evol 2018;35:719-33. [PMID: 29186559 DOI: 10.1093/molbev/msx304] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 11.0] [Reference Citation Analysis]
70 Urabe A, Sakamori R, Tahata Y, Yamada R, Imai Y, Hagiwara H, Tamura S, Fukui H, Yamada Y, Kaneko A, Hijioka T, Kodama T, Hikita H, Tatsumi T, Takehara T. Predictive factors of anemia during sofosbuvir and ribavirin therapy for genotype 2 chronic hepatitis C patients. Hepatol Res 2019;49:853-9. [PMID: 31009550 DOI: 10.1111/hepr.13354] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
71 Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017;142:83-122. [PMID: 28238877 DOI: 10.1016/j.antiviral.2017.02.014] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 18.6] [Reference Citation Analysis]
72 Goel A, Bhargava R, Rai P, Aggarwal R. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience. Indian J Gastroenterol 2017;36:227-34. [PMID: 28656492 DOI: 10.1007/s12664-017-0763-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
73 Garbuzenko DV. [The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection]. Vopr Virusol 2021;66:331-9. [PMID: 34738448 DOI: 10.36233/0507-4088-70] [Reference Citation Analysis]
74 Ahn YH, Park H, Lee MJ, Kim DH, Cho SB, Cho E, Jun CH, Choi SK. Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea. Gut Liver 2019;13:549-56. [PMID: 30970433 DOI: 10.5009/gnl18432] [Reference Citation Analysis]
75 Cousien A, Tran VC, Deuffic-burban S, Jauffret-roustide M, Mabileau G, Dhersin J, Yazdanpanah Y. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France. J Viral Hepat 2018;25:1197-207. [DOI: 10.1111/jvh.12919] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
76 Ansari MA, Aranday-Cortes E, Ip CL, da Silva Filipe A, Lau SH, Bamford C, Bonsall D, Trebes A, Piazza P, Sreenu V, Cowton VM, Hudson E, Bowden R, Patel AH, Foster GR, Irving WL, Agarwal K, Thomson EC, Simmonds P, Klenerman P, Holmes C, Barnes E, Spencer CC, McLauchlan J, Pedergnana V; STOP-HCV Consortium. Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. Elife 2019;8:e42463. [PMID: 31478835 DOI: 10.7554/eLife.42463] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
77 Pedergnana V, Smith D, Klenerman P, Barnes E, Spencer CC, Ansari MA; STOP-HCV Consortium. Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a. Hepatology 2016;64:1377-8. [PMID: 26945900 DOI: 10.1002/hep.28533] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
78 Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology 2016;151:651-659.e1. [PMID: 27456384 DOI: 10.1053/j.gastro.2016.07.020] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 12.0] [Reference Citation Analysis]
79 Ho SB, Monto A, Peyton A, Kaplan DE, Byrne S, Moon S, Copans A, Rossaro L, Roy A, Le H, Dvory-Sobol H, Zhu Y, Brainard DM, Guyer W, Shaikh O, Fuchs M, Morgan TR; VALOR study team. Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities. Clin Gastroenterol Hepatol 2017;15:282-8. [PMID: 27237429 DOI: 10.1016/j.cgh.2016.05.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
80 Ahmed A, Felmlee DJ. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses 2015;7:6716-29. [PMID: 26694454 DOI: 10.3390/v7122968] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 7.9] [Reference Citation Analysis]
81 Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27(11): 1006-1021 [PMID: 33776369 DOI: 10.3748/wjg.v27.i11.1006] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
82 Lionetti R, Piccolo P, Lenci I, Siciliano M, Visco-Comandini U, De Santis A, Pompili M, Milana M, Taibi C, Dell'Isola S, Montalbano M, Mastroianni C, Begini P, Garbuglia AR, Angelico M, D'Offizi G. Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study. Ann Hepatol 2019;18:434-8. [PMID: 31023614 DOI: 10.1016/j.aohep.2018.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
83 Aziz H, Aziz M, Gill ML. Analysis of Host and Viral-Related Factors Associated to Direct Acting Antiviral Response in Hepatitis C Virus Patients. Viral Immunol 2018;31:256-63. [PMID: 29664710 DOI: 10.1089/vim.2017.0124] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
84 Wang LS, D'Souza LS, Jacobson IM. Hepatitis C-A clinical review. J Med Virol. 2016;88:1844-1855. [PMID: 27097298 DOI: 10.1002/jmv.24554] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
85 Hull MW, Yoshida EM, Montaner JS. Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. Curr Infect Dis Rep 2016;18:22. [PMID: 27357277 DOI: 10.1007/s11908-016-0527-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
86 Marín MQ, Pérez P, Gómez CE, Sorzano CÓS, Esteban M, García-Arriaza J. Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression. Viruses 2018;10:E414. [PMID: 30096846 DOI: 10.3390/v10080414] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
87 Kim YM, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, Kang YW, Kim SH, Lee BS, Chae HB, Song MJ, Jang JW, Ko SY, Lee JD. Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study. Clin Mol Hepatol 2018;24:311-8. [PMID: 29865774 DOI: 10.3350/cmh.2017.0070] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
88 Ampuero J, Reddy KR, Romero-Gomez M. Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. World J Gastroenterol 2016; 22(22): 5285-5292 [PMID: 27298572 DOI: 10.3748/wjg.v22.i22.5285] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
89 Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WT, MacDonald DC, Agarwal K;  HCV Research; UK. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224-1231. [PMID: 26829205 DOI: 10.1016/j.jhep.2016.01.029] [Cited by in Crossref: 308] [Cited by in F6Publishing: 283] [Article Influence: 51.3] [Reference Citation Analysis]
90 Butsashvili M, Gvinjilia L, Kamkamidze G, Metreveli D, Dvali S, Rukhadze T, Gamkrelidze A, Nasrullah M, Shadaker S, Morgan J, Averhoff F. High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia. BMC Res Notes 2020;13:332. [PMID: 32653020 DOI: 10.1186/s13104-020-05173-4] [Reference Citation Analysis]
91 Abayasingam A, Leung P, Eltahla A, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Lloyd A, Rodrigo C; InC3 Study Group. Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing. Infect Genet Evol 2019;71:36-41. [PMID: 30853512 DOI: 10.1016/j.meegid.2019.02.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
92 Cárdaba-García ME, Abad-Lecha E, Calleja-Hernández MÁ. Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment. Libyan J Med 2021;16:1949797. [PMID: 34308801 DOI: 10.1080/19932820.2021.1949797] [Reference Citation Analysis]
93 Shah SR, Chowdhury A, Mehta R, Kapoor D, Duseja A, Koshy A, Shukla A, Sood A, Madan K, Sud R, Nijhawan S, Pawan R, Prasad M, Kersey K, Jiang D, Svarovskaia E, Doehle B, Kanwar B, Subramanian M, Acharya SK, Sarin S. Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India. J Viral Hepat 2017;24:371-9. [PMID: 27933698 DOI: 10.1111/jvh.12654] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
94 He T, Lopez-Olivo MA, Hur C, Chhatwal J. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. Aliment Pharmacol Ther. 2017;46:711-721. [PMID: 28836278 DOI: 10.1111/apt.14271] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
95 Conti F, Brillanti S, Buonfiglioli F, Vukotic R, Morelli MC, Lalanne C, Massari M, Foschi FG, Bernabucci V, Serio I, Prati GM, Negri E, Badia L, Caraceni P, Muratori P, Vitale G, Porro A, Morotti M, Mazzella G, Andreone P. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. J Viral Hepat. 2017;24:454-463. [PMID: 27976461 DOI: 10.1111/jvh.12663] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
96 Laurito MP, Silva GF, Cheinquer H, Sharma R, Verna E, Parise ER. DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS? Arq Gastroenterol 2018;55:179-83. [PMID: 30043870 DOI: 10.1590/S0004-2803.201800000-32] [Reference Citation Analysis]
97 Zarębska-Michaluk D, Stępień PM, Paluch K, Pabjan P. Retreatment of symptomatic hepatitis C virus genotype 3 associated mixed cryoglobulinemia with sofosbuvir and ribavirin: a case report. Clin Exp Hepatol 2018;4:100-3. [PMID: 29904727 DOI: 10.5114/ceh.2018.75960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Wu S, Chu C, Su C, Lin C, Lee S, Wang Y, Lee F, Huang Y, Hou M. Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan. Journal of the Chinese Medical Association 2019;82:693-8. [DOI: 10.1097/jcma.0000000000000148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
99 Haider SA, Ahmad B, Ali S, Haider A, Bashir S, Mahmood N. Sofosbuvir and Ribavirin Combination Therapy Response in Various Hepatitis C Virus Genotypes in Peshawar, Khyber Pakhtunkhwa. Jundishapur J Microbiol 2020;13. [DOI: 10.5812/jjm.99625] [Reference Citation Analysis]
100 Bonaventura A, Montecucco F. Sofosbuvir/velpatasvir: A promising combination. World J Hepatol 2016; 8(19): 785-789 [PMID: 27429714 DOI: 10.4254/wjh.v8.i19.785] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
101 Rattanavipapong W, Anothaisintawee T, Teerawattananon Y. Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. PLoS One 2018;13:e0193112. [PMID: 29466415 DOI: 10.1371/journal.pone.0193112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
102 Welker MW, Luhne S, Lange CM, Vermehren J, Farnik H, Herrmann E, Welzel T, Zeuzem S, Sarrazin C. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol. 2016;64:790-799. [PMID: 26658684 DOI: 10.1016/j.jhep.2015.11.034] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 7.0] [Reference Citation Analysis]
103 Ramamurthy N, Marchi E, Ansari MA, Pedergnana V, Mclean A, Hudson E, Bowden R, Spencer CCA, Barnes E, Klenerman P; STOP HCV consortium. Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C. Hepatology 2018;68:859-71. [PMID: 29534310 DOI: 10.1002/hep.29877] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
104 Flisiak R, Pogorzelska J, Berak H, Horban A, Orłowska I, Simon K, Tuchendler E, Madej G, Piekarska A, Jabłkowski M, Deroń Z, Mazur W, Kaczmarczyk M, Janczewska E, Pisula A, Smykał J, Nowak K, Matukiewicz M, Halota W, Wernik J, Sikorska K, Mozer-Lisewska I, Rozpłochowski B, Garlicki A, Tomasiewicz K, Krzowska-Firych J, Baka-Ćwierz B, Kryczka W, Zarębska-Michaluk D, Olszok I, Boroń-Kaczmarska A, Sobala-Szczygieł B, Szlauer B, Korcz-Ondrzejek B, Sieklucki J, Pleśniak R, Ruszała A, Postawa-Kłosińska B, Citko J, Lachowicz-Wawrzyniak A, Musialik J, Jezierska E, Dobracki W, Dobracka B, Hałubiec J, Krygier R, Strokowska A, Chomczyk W, Witczak-Malinowska K. Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study. Clin Exp Hepatol 2016;2:138-43. [PMID: 28856278 DOI: 10.5114/ceh.2016.63870] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
105 Sarwar S, Khan AA. Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference? Pak J Med Sci 2017;33:37-41. [PMID: 28367169 DOI: 10.12669/pjms.331.12163] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
106 Hojati SA, Maserat E, Ghorbani M, Safarpour A, Fattehi MR. Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective? Med Arch 2018;72:325-9. [PMID: 30524163 DOI: 10.5455/medarh.2018.72.325-329] [Reference Citation Analysis]
107 Zanaga LP, Miotto N, Mendes LC, Stucchi RS, Vigani AG. Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents. Braz J Med Biol Res 2016;49:e5504. [PMID: 27783808 DOI: 10.1590/1414-431X20165504] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
108 Tsai WL, Wang CF, Cheng JS, Chen WC, Bair MJ, Lo CC. Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience. PLoS One 2020;15:e0227424. [PMID: 31923251 DOI: 10.1371/journal.pone.0227424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
109 Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N, Chirino-Sprung RA, Cisneros-Garza L, Dehesa-Violante M, Flores-Calderón J, Flores-Gaxiola A, García-Juárez I, González-Huezo MS, González-Moreno EI, Higuera-de la Tijera F, Kershenobich-Stalnikowitz D, López-Méndez E, Malé-Velázquez R, Marín-López E, Mata-Marín JA, Méndez-Sánchez N, Monreal-Robles R, Moreno-Alcántar R, Muñoz-Espinosa L, Navarro-Alvarez S, Pavia-Ruz N, Pérez-Ríos AM, Poo-Ramírez JL, Rizo-Robles MT, Sánchez-Ávila JF, Sandoval-Salas R, Torre A, Torres-Ibarra R, Trejo-Estrada R, Velarde-Ruiz Velasco JA, Wolpert-Barraza E, Bosques-Padilla F. The Mexican consensus on the treatment of hepatitis C. Rev Gastroenterol Mex (Engl Ed) 2018;83:275-324. [PMID: 29803325 DOI: 10.1016/j.rgmx.2017.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
110 Ferreira VL, Tonin FS, Assis Jarek NA, Ramires Y, Pontarolo R. Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. Clin Drug Investig 2017;37:635-46. [PMID: 28409482 DOI: 10.1007/s40261-017-0521-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
111 Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24:169-229. [PMID: 30092624 DOI: 10.3350/cmh.2018.1004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
112 Nelson DR, Peter J. Hepatitis C virus: how to provide the best treatment with what I have. Liver Int 2016;36 Suppl 1:58-61. [PMID: 26725898 DOI: 10.1111/liv.13004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
113 Fares MY, Abdelwahab NS, Abdelrahman MM, Abdel-Rahman HM. Determination of sofosbuvir with two co-administered drugs; paracetamol and DL-methionine by two chromatographic methods. Application to a pharmacokinetic study. Bioanalysis 2019;11:349-64. [PMID: 30873855 DOI: 10.4155/bio-2018-0191] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
114 Maasoumy B, Vermehren J, Welker MW, Bremer B, Perner D, Höner Zu Siederdissen C, Deterding K, Lehmann P, Cloherty G, Reinhardt B, Pawlotsky JM, Manns MP, Zeuzem S, Cornberg M, Wedemeyer H, Sarrazin C. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. J Hepatol 2016;65:473-82. [PMID: 27085252 DOI: 10.1016/j.jhep.2016.04.006] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 8.8] [Reference Citation Analysis]
115 Wirth S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, Balistreri WF, Lin CH, Hardikar W, Kersey K, Massetto B, Kanwar B, Brainard DM, Shao J, Svarovskaia E, Kirby B, Arnon R, Murray KF, Schwarz KB. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017;66:1102-1110. [PMID: 28543053 DOI: 10.1002/hep.29278] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 14.4] [Reference Citation Analysis]
116 Colombo MG, Musabaev EI, Ismailov UY, Zaytsev IA, Nersesov AV, Anastasiy IA, Karpov IA, Golubovska OA, Kaliaskarova KS, AC R, Hadigal S. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. World J Gastroenterol 2019; 25(29): 3897-3919 [PMID: 31413526 DOI: 10.3748/wjg.v25.i29.3897] [Reference Citation Analysis]
117 [DOI: 10.1101/157768] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
118 Sood A, Midha V, Mahajan R, Narang V, Mehta V, Wander P, Sharma S, Kaur K, Singh D. Results of sofosbuvir-based combination therapy for chronic hepatitis C cohort of Indian patients in real-life clinical practice. J Gastroenterol Hepatol 2017;32:894-900. [PMID: 27787910 DOI: 10.1111/jgh.13628] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
119 Meewan I, Zhang X, Roy S, Ballatore C, O'Donoghue AJ, Schooley RT, Abagyan R. Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant. ACS Omega 2019;4:16999-7008. [PMID: 31646247 DOI: 10.1021/acsomega.9b02491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
120 Nelson M, Rubio R, Lazzarin A, Romanova S, Luetkemeyer A, Conway B, Molina J, Xu D, Srinivasan S, Portsmouth S. Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients. Journal of Interferon & Cytokine Research 2017;37:103-11. [DOI: 10.1089/jir.2016.0082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
121 Mikolas LA, Jacques K, Huq M, Krasner C, Mambourg SE. Utilizing Clinical Pharmacist Specialist to Manage Hepatitis C Virus Patients on Direct-Acting Antiviral Therapy. J Pharm Pract 2019;32:655-63. [PMID: 29783912 DOI: 10.1177/0897190018777345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
122 Zachoval R, Jung MC. [Chronic Hepatitis C - Therapeutic Options in 2016]. MMW Fortschr Med 2016;158 Suppl 1:54-7. [PMID: 27259905 DOI: 10.1007/s15006-016-8329-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
123 Abd-Elsalam S, Sharaf-Eldin M, Soliman S, Elfert A, Badawi R, Ahmad YK. Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol. 2018;163:51-56. [PMID: 28983675 DOI: 10.1007/s00705-017-3573-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
124 Maan R, van der Meer AJ. Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res 2016;5:F1000 Faculty Rev-367. [PMID: 27006761 DOI: 10.12688/f1000research.7399.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
125 Shahnazarian V, Ramai D, Reddy M, Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann Gastroenterol 2018;31:541-51. [PMID: 30174390 DOI: 10.20524/aog.2018.0281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
126 Gorka S, Gulzar GM, Yattoo GN, Sodhi JS, Dar GA, Laway MA, Kaushik S, Dhar N, Mushfiq S, Aziz RA. Genotype 1 and 3 Response to Velpatasvir and Sofosbuvir in Chronic Hepatitis C in the Kashmiri Population: An Observational Study. J Clin Exp Hepatol 2020;10:155-62. [PMID: 32189931 DOI: 10.1016/j.jceh.2019.07.003] [Reference Citation Analysis]
127 Charlton MR, Gane EJ, Shukla A, Dashtseren B, Duger D, Muljono DH, Payawal DA, Jargalsaikhan G, Purnomo HD, Cua IH, Hasan I, Sollano J Jr, Win KM, Lesmana LA, Salih M, Thi Thu Thuy P, Shankar R, Saraswat VA. International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. Transplantation 2019;103:733-46. [PMID: 30335692 DOI: 10.1097/TP.0000000000002453] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
128 Wang Y, Rao H, Chi X, Li B, Liu H, Wu L, Zhang H, Liu S, Zhou G, Li N, Niu J, Wei L, Zhao J. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality. EBioMedicine 2019;46:227-35. [PMID: 31345785 DOI: 10.1016/j.ebiom.2019.07.043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
129 Cornberg M, Petersen J, Schober A, Mauss S, Böker KHW, Link R, Günther R, Serfert Y, Pfeiffer-vornkahl H, Manns MP, Sarrazin C, Hüppe D, Berg T, Niederau C. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther 2017;45:688-700. [DOI: 10.1111/apt.13925] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
130 Perera S, Bonsall D, Niriella MA, Allen A, Peries AC, Nelumdeniya UB, Dissanayake R, Silva I, de Cesare M, Klenerman P, Weatherall DJ, Roberts DJ, Premawardhena AP. Transfusion-transmitted hepatitis C: A cluster of cases in transfusion-dependent thalassaemia patients in Sri Lanka. Transfus Med 2020;30:377-83. [PMID: 31916330 DOI: 10.1111/tme.12660] [Reference Citation Analysis]
131 Padhi S, Maharshi S, Gupta GK, Garg K, Nijhawan S. Efficacy and Safety of Direct Acting Antiviral Therapy for Chronic Hepatitis C in Thalassemic Children. J Pediatr Hematol Oncol. 2018;40:511-514. [PMID: 29771862 DOI: 10.1097/mph.0000000000001217] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
132 Fathi HM, Abdel Wahed WY, Gomaa AA, Hassan EA, Eid HM, Reheem FA, Senara SH. A prospective study in hepatitis C virus treatment-naïve patients showing rheumatologic extra-hepatic manifestations of hepatitis C with associated risk factors: efficacy and safety using sofosbuvir-based direct antiviral therapy. Egypt Rheumatol Rehabil 2020;47. [DOI: 10.1186/s43166-020-00023-4] [Reference Citation Analysis]
133 Morisco F, Granata R, Camera S, Ippolito A, Milella M, Conti F, Masetti C, Smedile A, Tundo P, Santantonio T, Valvano MR, Termite A, Gatti P, Messina V, Iacobellis A, Librandi M, Caporaso N, Andriulli A; ITAL-C consortium. Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3. United European Gastroenterol J 2018;6:225-37. [PMID: 29511552 DOI: 10.1177/2050640617717158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
134 Wilson EM, Rosenthal ES, Kattakuzhy S, Tang L, Kottilil S. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. Clin Microbiol Rev 2017;30:23-42. [PMID: 27795306 DOI: 10.1128/CMR.00037-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
135 Sirinawasatien A, Techasirioangkun T. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand. PLoS One 2020;15:e0229517. [PMID: 32106270 DOI: 10.1371/journal.pone.0229517] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
136 Yeon JE. Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans? Clin Mol Hepatol 2018;24:294-6. [PMID: 30200750 DOI: 10.3350/cmh.2018.1009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
137 Smith D, Magri A, Bonsall D, Ip CLC, Trebes A, Brown A, Piazza P, Bowden R, Nguyen D, Ansari MA, Simmonds P, Barnes E; STOP-HCV Consortium. Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. Hepatology 2019;69:1861-72. [PMID: 29425396 DOI: 10.1002/hep.29837] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
138 Łucejko M, Parfieniuk-kowerda A, Flisiak R. Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection. Expert Opinion on Pharmacotherapy 2016;17:1153-64. [DOI: 10.1080/14656566.2016.1176143] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
139 Jung YK. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3]. Korean J Gastroenterol 2016;67:132-6. [PMID: 26996182 DOI: 10.4166/kjg.2016.67.3.132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
140 Gallego I, Sheldon J, Moreno E, Gregori J, Quer J, Esteban JI, Rice CM, Domingo E, Perales C. Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus. Antimicrob Agents Chemother 2016;60:3786-93. [PMID: 27067341 DOI: 10.1128/AAC.00581-16] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
141 Ansari MA, Pedergnana V, L C Ip C, Magri A, Von Delft A, Bonsall D, Chaturvedi N, Bartha I, Smith D, Nicholson G, McVean G, Trebes A, Piazza P, Fellay J, Cooke G, Foster GR, Hudson E, McLauchlan J, Simmonds P, Bowden R, Klenerman P, Barnes E, Spencer CCA; STOP-HCV Consortium. Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nat Genet 2017;49:666-73. [PMID: 28394351 DOI: 10.1038/ng.3835] [Cited by in Crossref: 79] [Cited by in F6Publishing: 60] [Article Influence: 15.8] [Reference Citation Analysis]
142 Øvrehus ALH, Krarup H, Birkemose I, Holm DK, Mössner B, Ernst A, Christensen PB. Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial. J Hepatol 2018;68:840-2. [PMID: 29223370 DOI: 10.1016/j.jhep.2017.11.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
143 Naveed M, Ali A, Sheikh N, Rafique S, Idrees M. Expression of TRIM22 mRNA in chronic hepatitis C patients treated with direct-acting antiviral drugs. APMIS 2020;128:326-34. [PMID: 31863490 DOI: 10.1111/apm.13024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
144 Kao JH, Chien RN, Chang TT, Peng CY, Hu TH, Lo GH, Wang HY, Chen JJ, Yang JC, Knox SJ, Han L, Mo H, Mathias A, Brainard DM, Sheen IS, Hsu YC, Chu CJ, Chuang WL. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int 2016;36:1101-7. [PMID: 26835876 DOI: 10.1111/liv.13082] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
145 Zeuzem S. Treatment Options in Hepatitis C. Dtsch Arztebl Int 2017;114:11-21. [PMID: 28143635 DOI: 10.3238/arztebl.2017.0011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
146 Rockstroh JK, Hardy WD. Current treatment options for hepatitis C patients co-infected with HIV. Expert Rev Gastroenterol Hepatol 2016;10:689-95. [PMID: 26799571 DOI: 10.1586/17474124.2016.1145545] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
147 Restelli U, Alberti A, Lazzarin A, Bonfanti M, Nappi C, Croce D. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy. Eur J Health Econ 2018;19:37-44. [PMID: 28008546 DOI: 10.1007/s10198-016-0865-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
148 Wong YJ, Cheen MH, Hsiang JC, Kumar R, Tan J, Teo EK, Thurairajah PH. Economic evaluation of direct-acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore. JGH Open 2019;3:210-6. [PMID: 31276038 DOI: 10.1002/jgh3.12139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
149 Tang L, Kamat M, Shukla A, Vora M, Kalal C, Kottilil S, Shah S. Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C. Interdiscip Perspect Infect Dis 2018;2018:9124604. [PMID: 30364048 DOI: 10.1155/2018/9124604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
150 Macken L, Gelson W, Priest M, Abouda G, Barclay S, Fraser A, Healy B, Irving W, Verma S. Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort. J Med Virol. 2019;91:1979-1988. [PMID: 31329295 DOI: 10.1002/jmv.25552] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
151 de Ávila AI, Gallego I, Soria ME, Gregori J, Quer J, Esteban JI, Rice CM, Domingo E, Perales C. Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir. PLoS One 2016;11:e0164691. [PMID: 27755573 DOI: 10.1371/journal.pone.0164691] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
152 Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, Lim JK, Darling J, Pockros P, Galati JS, Frazier LM, Alqahtani S, Sulkowski MS, Vainorius M, Akushevich L, Fried MW, Zeuzem S; HCV-TARGET Study Group. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut 2017;66:1844-52. [PMID: 27418632 DOI: 10.1136/gutjnl-2016-311609] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 8.8] [Reference Citation Analysis]
153 Tsertsvadze T, Gamkrelidze A, Nasrullah M, Sharvadze L, Morgan J, Shadaker S, Gvinjilia L, Butsashvili M, Metreveli D, Kerashvili V, Ezugbaia M, Chkhartishvili N, Abutidze A, Kvaratskhelia V, Averhoff F. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia. BMC Infect Dis 2020;20:30. [PMID: 31924172 DOI: 10.1186/s12879-019-4741-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
154 Moreno E, Gallego I, Gregori J, Lucía-Sanz A, Soria ME, Castro V, Beach NM, Manrubia S, Quer J, Esteban JI, Rice CM, Gómez J, Gastaminza P, Domingo E, Perales C. Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment. J Virol 2017;91:e02505-16. [PMID: 28275194 DOI: 10.1128/JVI.02505-16] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
155 Cardona-Gonzalez MG, Goldman JD, Narayan L, Brainard DM, Kowdley KV. Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation. Hepatol Commun. 2018;2:1446-1450. [PMID: 30556034 DOI: 10.1002/hep4.1280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
156 Feld JJ, Foster GR. Second generation direct-acting antivirals – Do we expect major improvements? Journal of Hepatology 2016;65:S130-42. [DOI: 10.1016/j.jhep.2016.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
157 Tmu N, Kumar A, Sharma P, Singla V, Bansal N, Arora A. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis. J Clin Exp Hepatol 2019;9:4-12. [PMID: 30765933 DOI: 10.1016/j.jceh.2018.02.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
158 Soria ME, García-Crespo C, Martínez-González B, Vázquez-Sirvent L, Lobo-Vega R, de Ávila AI, Gallego I, Chen Q, García-Cehic D, Llorens-Revull M, Briones C, Gómez J, Ferrer-Orta C, Verdaguer N, Gregori J, Rodríguez-Frías F, Buti M, Esteban JI, Domingo E, Quer J, Perales C. Amino Acid Substitutions Associated with Treatment Failure for Hepatitis C Virus Infection. J Clin Microbiol 2020;58:e01985-20. [PMID: 32999010 DOI: 10.1128/JCM.01985-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]